JP2017508794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508794A5 JP2017508794A5 JP2016573680A JP2016573680A JP2017508794A5 JP 2017508794 A5 JP2017508794 A5 JP 2017508794A5 JP 2016573680 A JP2016573680 A JP 2016573680A JP 2016573680 A JP2016573680 A JP 2016573680A JP 2017508794 A5 JP2017508794 A5 JP 2017508794A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- haloalkyl
- independently
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 102100025271 2-acylglycerol O-acyltransferase 2 Human genes 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- 101710186725 2-acylglycerol O-acyltransferase 2 Proteins 0.000 claims 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 3
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 3
- 101000577113 Homo sapiens 2-acylglycerol O-acyltransferase 2 Proteins 0.000 claims 3
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- -1 OBn Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004995 haloalkylthio group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 101001094079 Homo sapiens Sodium- and chloride-dependent GABA transporter 2 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 102100035242 Sodium- and chloride-dependent GABA transporter 2 Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 230000004217 heart function Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 *C(*)(C(*)(*)NC1=O)C(C(C=CC=CC=CC=C)=C)=C1N(C(N)=O)N=N Chemical compound *C(*)(C(*)(*)NC1=O)C(C(C=CC=CC=CC=C)=C)=C1N(C(N)=O)N=N 0.000 description 9
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949490P | 2014-03-07 | 2014-03-07 | |
| US61/949,490 | 2014-03-07 | ||
| PCT/US2015/018870 WO2015134699A1 (en) | 2014-03-07 | 2015-03-05 | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508794A JP2017508794A (ja) | 2017-03-30 |
| JP2017508794A5 true JP2017508794A5 (enExample) | 2018-03-15 |
| JP6449919B2 JP6449919B2 (ja) | 2019-01-09 |
Family
ID=52686513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573680A Active JP6449919B2 (ja) | 2014-03-07 | 2015-03-05 | テトラゾロン置換のジヒドロピリジノンｍｇａｔ２阻害剤 |
Country Status (32)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
| MY176921A (en) * | 2014-03-07 | 2020-08-26 | Bristol Myers Squibb Co | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors |
| ES2666569T3 (es) | 2014-06-11 | 2018-05-07 | Bristol-Myers Squibb Company | Piridinonas sustituidas como inhibidores de MGAT2 |
| CN105218518B (zh) * | 2015-09-15 | 2018-01-12 | 青岛科标检测研究院有限公司 | 一种可用于制备供热采暖系统清洗剂的化合物及其制备方法 |
| WO2017069224A1 (ja) * | 2015-10-22 | 2017-04-27 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するスピロ環誘導体 |
| JPWO2017110841A1 (ja) * | 2015-12-21 | 2018-10-11 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体 |
| JP2020158390A (ja) * | 2017-06-20 | 2020-10-01 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物 |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| JP7608166B2 (ja) | 2019-01-11 | 2025-01-06 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
| CN118215478A (zh) * | 2021-09-08 | 2024-06-18 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| EP4201923A1 (en) | 2021-12-23 | 2023-06-28 | Karl-Franzens-Universität Graz | 5-substituted 2,3-dihydropyridin-4-ones and process for preparing the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US20100016365A1 (en) | 2008-07-17 | 2010-01-21 | Auspex Pharmaceuticals, Inc. | Substituted 4-amino-piperidines |
| US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
| JP6417405B2 (ja) | 2013-05-29 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ジヒドロピリジノンｍｇａｔ２阻害剤 |
| MY176921A (en) * | 2014-03-07 | 2020-08-26 | Bristol Myers Squibb Co | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors |
| MX2016011105A (es) | 2014-03-07 | 2016-12-12 | Bristol Myers Squibb Co | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. |
-
2015
- 2015-03-05 MY MYPI2016703163A patent/MY176921A/en unknown
- 2015-03-05 WO PCT/US2015/018870 patent/WO2015134699A1/en not_active Ceased
- 2015-03-05 CA CA2941951A patent/CA2941951C/en active Active
- 2015-03-05 SM SM20190256T patent/SMT201900256T1/it unknown
- 2015-03-05 DK DK15710686.5T patent/DK3114120T3/da active
- 2015-03-05 EP EP15710686.5A patent/EP3114120B1/en active Active
- 2015-03-05 EA EA201691670A patent/EA030561B1/ru not_active IP Right Cessation
- 2015-03-05 LT LTEP15710686.5T patent/LT3114120T/lt unknown
- 2015-03-05 HU HUE15710686 patent/HUE044272T2/hu unknown
- 2015-03-05 SI SI201530657T patent/SI3114120T1/sl unknown
- 2015-03-05 US US15/123,773 patent/US9688656B2/en active Active
- 2015-03-05 TR TR2019/06325T patent/TR201906325T4/tr unknown
- 2015-03-05 KR KR1020167027385A patent/KR102336371B1/ko active Active
- 2015-03-05 BR BR112016019487-0A patent/BR112016019487B1/pt active IP Right Grant
- 2015-03-05 JP JP2016573680A patent/JP6449919B2/ja active Active
- 2015-03-05 NZ NZ72489015A patent/NZ724890A/en unknown
- 2015-03-05 PT PT15710686T patent/PT3114120T/pt unknown
- 2015-03-05 RS RS20190436A patent/RS58740B1/sr unknown
- 2015-03-05 AU AU2015227140A patent/AU2015227140B2/en active Active
- 2015-03-05 PL PL15710686T patent/PL3114120T3/pl unknown
- 2015-03-05 HR HRP20190668TT patent/HRP20190668T1/hr unknown
- 2015-03-05 ES ES15710686T patent/ES2719713T3/es active Active
- 2015-03-05 CN CN201580012204.XA patent/CN106061968B/zh active Active
- 2015-03-05 MA MA39335A patent/MA39335B1/fr unknown
- 2015-03-05 PE PE2016001576A patent/PE20161369A1/es active IP Right Grant
- 2015-03-05 MX MX2016011223A patent/MX2016011223A/es active IP Right Grant
- 2015-03-05 SG SG11201607393XA patent/SG11201607393XA/en unknown
-
2016
- 2016-08-01 PH PH12016501517A patent/PH12016501517B1/en unknown
- 2016-09-01 IL IL247592A patent/IL247592B/en active IP Right Grant
- 2016-09-06 ZA ZA2016/06174A patent/ZA201606174B/en unknown
- 2016-09-06 CL CL2016002238A patent/CL2016002238A1/es unknown
-
2017
- 2017-05-23 US US15/602,515 patent/US9896431B2/en active Active
-
2018
- 2018-01-10 US US15/866,871 patent/US10093650B2/en active Active
- 2018-08-30 US US16/117,107 patent/US10329273B2/en active Active
-
2019
- 2019-05-08 CY CY20191100492T patent/CY1121746T1/el unknown
- 2019-05-09 US US16/407,441 patent/US10538505B2/en active Active
- 2019-11-26 US US16/695,239 patent/US11479538B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508794A5 (enExample) | ||
| JP2017508795A5 (enExample) | ||
| JP2016520128A5 (enExample) | ||
| JP2017514856A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP5786034B2 (ja) | 脂質異常症の治療に適したヘテロ環式化合物 | |
| JP2016506960A5 (enExample) | ||
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| JP2014508811A5 (enExample) | ||
| JP2017511794A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| RU2017126128A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| RU2015100901A (ru) | Производные эфира гетероарилкарбоновой кислоты | |
| JP2016500063A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2016531126A5 (enExample) | ||
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| RU2019133530A (ru) | ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8 | |
| SI3140296T1 (en) | PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE | |
| JP2016528273A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 |